Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 133 articles: HTML format Text format

Single Articles

July 2018
1. LAMMERS PE, Dank M, Masetti R, Abbas R, et al
   Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
   Br J Cancer. 2018 Jul 13. pii: 10.1038/s41416-018-0147.
   PubMed     Text format     Abstract available
   
   
   
2. STERLE HA, Nicoud MB, Massari NA, Taquez Delgado MA, et al
   Immunomodulatory role of histamine H4 receptor in breast cancer.
   Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0173.
   PubMed     Text format     Abstract available
   
   
   June 2018
3. LO LL, Milne RL, Liao Y, Cuzick J, et al
   Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
   Br J Cancer. 2018 Jun 21. pii: 10.1038/s41416-018-0120.
   PubMed     Text format     Abstract available
   
   
   
4. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
   G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
   Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
   PubMed     Text format     Abstract available
   
   
   
5. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
   Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
   Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
   PubMed     Text format     Abstract available
   
   
   
6. DERKS MGM, Bastiaannet E, Kiderlen M, Hilling DE, et al
   Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.
   Br J Cancer. 2018 Jun 7. pii: 10.1038/s41416-018-0090.
   PubMed     Text format     Abstract available
   
   
   
7. ROHAN TE, Miller CA, Li T, Wang Y, et al
   Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
   Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0089.
   PubMed     Text format     Abstract available
   
   
   
8. TUNG NM, Garber JE
   BRCA1/2 testing: therapeutic implications for breast cancer management.
   Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
   PubMed     Text format     Abstract available
   
   
   
9. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
   RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
   Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
   PubMed     Text format     Abstract available
   
   
   May 2018
10. WEIN L, Luen SJ, Savas P, Salgado R, et al
    Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
    PubMed     Text format     Abstract available
    
    
    
11. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    PubMed     Text format     Abstract available
    
    
    
12. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    PubMed     Text format    
    
    
    
13. MORTAZAVI SMJ
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    PubMed     Text format    
    
    
    
14. FRENCH DP, Southworth J, Howell A, Harvie M, et al
    Psychological impact of providing women with personalised 10-year breast cancer risk estimates.
    Br J Cancer. 2018 May 8. pii: 10.1038/s41416-018-0069.
    PubMed     Text format     Abstract available
    
    
    
15. CHEN S, Wang H, Li Z, You J, et al
    Interaction of WBP2 with ERalpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0119.
    PubMed     Text format     Abstract available
    
    
    
16. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Text format     Abstract available
    
    
    April 2018
17. BHARTI R, Dey G, Das AK, Mandal M, et al
    Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0078.
    PubMed     Text format     Abstract available
    
    
    
18. ORECCHIONI S, Talarico G, Labanca V, Calleri A, et al
    Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0076.
    PubMed     Text format     Abstract available
    
    
    
19. LIIKANEN JS, Leidenius MH, Joensuu H, Vironen JH, et al
    Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study.
    Br J Cancer. 2018 Apr 24. pii: 10.1038/s41416-018-0052.
    PubMed     Text format     Abstract available
    
    
    March 2018
20. JOSEPH C, Macnamara O, Craze M, Russell R, et al
    Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
    PubMed     Text format     Abstract available
    
    
    
21. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
    Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
    PubMed     Text format     Abstract available
    
    
    
22. MCNAMARA KM, Guestini F, Sauer T, Touma J, et al
    In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0034.
    PubMed     Text format     Abstract available
    
    
    
23. GYORFFY B, Pongor L, Bottai G, Li X, et al
    An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0030.
    PubMed     Text format     Abstract available
    
    
    
24. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Text format     Abstract available
    
    
    
25. SAUERBREI W, Haeussler T
    Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0023.
    PubMed     Text format    
    
    
    
26. POUJADE FA, Mannion A, Brittain N, Theodosi A, et al
    WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0056.
    PubMed     Text format     Abstract available
    
    
    
27. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0032.
    PubMed     Text format    
    
    
    February 2018
28. REMSIK J, Fedr R, Navratil J, Bino L, et al
    Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
    Br J Cancer. 2018 Feb 20. pii: bjc2017497. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
29. DOSS M
    Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
    Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
30. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
    Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    January 2018
31. LEGLER K, Rosprim R, Karius T, Eylmann K, et al
    Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017472. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
32. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
    Immune gene expression and response to chemotherapy in advanced breast cancer.
    Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
33. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
    Loss in working years after a breast cancer diagnosis.
    Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
34. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
35. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
    Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
36. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017437. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    December 2017
37. REDDY SM, Barcenas CH, Sinha AK, Hsu L, et al
    Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Br J Cancer. 2017 Dec 12. pii: bjc2017379. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    November 2017
38. CRAZE ML, Cheung H, Jewa N, Coimbra NDM, et al
    MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
39. NANDY SB, Orozco A, Lopez-Valdez R, Roberts R, et al
    Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.
    Br J Cancer. 2017;117:1665-1675.
    PubMed     Text format     Abstract available
    
    
    
40. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    October 2017
41. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available
    
    
    
42. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
43. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available
    
    
    
44. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Text format     Abstract available
    
    
    
45. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
46. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
47. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
48. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
49. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available
    
    
    August 2017
50. CAPELAN M, Battisti NML, McLoughlin A, Maidens V, et al
    The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
51. GURVITS N, Loyttyniemi E, Nykanen M, Kuopio T, et al
    Separase is a marker for prognosis and mitotic activity in breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
52. ALESKANDARANY MA, Sonbul S, Surridge R, Mukherjee A, et al
    Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
    Br J Cancer. 2017 Aug 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
53. OKONJI DO, Sinha R, Phillips I, Fatz D, et al
    Comprehensive geriatric assessment in 326 older women with early breast cancer.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
54. SHI F, Zhang Q, Liang Z, Zhang M, et al
    One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
55. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available
    
    
    July 2017
56. SMITH A, Murphy L, Zgaga L, Barron TI, et al
    Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.
    Br J Cancer. 2017 Jul 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
57. JIANG L, Luan Y, Miao X, Sun C, et al
    Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
58. VAN MAAREN MC, Bretveld RW, Jobsen JJ, Veenstra RK, et al
    The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival.
    Br J Cancer. 2017;117:179-188.
    PubMed     Text format     Abstract available
    
    
    
59. WU J, Zhou XJ, Sun X, Xia TS, et al
    RBM38 is involved in TGF-beta-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
60. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available
    
    
    
61. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available
    
    
    
62. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available
    
    
    
63. MAVROUDIS D, Saloustros E, Boukovinas I, Papakotoulas P, et al
    Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
64. LEVASSEUR N, Chia SK
    Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
65. MOSKOWITZ CS, Chou JF, Sklar CA, Barnea D, et al
    Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
66. CUI YX, Bradbury R, Flamini V, Wu B, et al
    MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
67. CHEN LL, Zhang ZJ, Yi ZB, Li JJ, et al
    MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    May 2017
68. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    April 2017
69. HEQUET D, Huchon C, Baffert S, Alran S, et al
    Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
70. KWIATKOWSKI F, Mouret-Reynier MA, Duclos M, Bridon F, et al
    Long-term improvement of breast cancer survivors' quality of life by a 2-week group physical and educational intervention: 5-year update of the 'PACThe' trial.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
71. ROMAN M, Quintana MJ, Ferrer J, Sala M, et al
    Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
72. TRAN WT, Gangeh MJ, Sannachi L, Chin L, et al
    Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
73. MESCI A, Huang X, Taeb S, Jahangiri S, et al
    Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
74. MILLER AB
    Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study'.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    March 2017
75. CHIARELLI AM, Muradali D, Blackmore KM, Smith CR, et al
    Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
76. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
77. SHEN J, Liao Y, Hopper JL, Goldberg M, et al
    Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
78. MANDL MM, Zhang S, Ulrich M, Schmoeckel E, et al
    Inhibition of Cdk5 induces cell death of tumor-initiating cells.
    Br J Cancer. 2017;116:912-922.
    PubMed     Text format     Abstract available
    
    
    
79. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
80. ROUZIER R, Uzan C, Rousseau A, Guillot E, et al
    Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NO
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
81. ALTUNDAG K
    Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    
82. FUJII T, Ueno NT
    Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
    February 2017
83. BRESLIN S, Lowry MC, O'Driscoll L
    Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
    Br J Cancer. 2017;116:620-625.
    PubMed     Text format     Abstract available
    
    
    
84. PINDER SE, Campbell AF, Bartlett JM, Marshall A, et al
    Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
85. CATALANO OA, Horn GL, Signore A, Iannace C, et al
    PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
86. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
87. YIP C, Foidart P, Somja J, Truong A, et al
    MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
88. MORRELL S, Taylor R, Roder D, Robson B, et al
    Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
89. MOYNAHAN ME, Chen D, He W, Sung P, et al
    Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
90. DE PLACIDO S, De Angelis C, Giuliano M, Pizzi C, et al
    Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    Br J Cancer. 2017 Feb 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    
91. HANSEN MF, Jensen SO, Fuchtbauer EM, Martensen PM, et al
    High folic acid diet enhances tumour growth in PyMT-induced breast cancer.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available
    
    
    January 2017
92. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
93. FUJII T, Kogawa T, Wu J, Sahin AA, et al
    Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
94. KAZARIAN A, Blyuss O, Metodieva G, Gentry-Maharaj A, et al
    Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
95. PARRA K, Valenzuela P, Lerma N, Gallegos A, et al
    Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
96. ROCHEFORT P, Chabaud S, Pierga JY, Tredan O, et al
    Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
97. SOOD D, Johnson N, Jain P, Siskos AP, et al
    CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
    Br J Cancer. 2017;116:382-388.
    PubMed     Text format     Abstract available
    
    
    December 2016
98. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
99. JOHNS LE, Coleman DA, Swerdlow AJ, Moss SM, et al
    Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available
    
    
    
100. UUSITALO E, Kallionpaa RA, Kurki S, Rantanen M, et al
     Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.
     Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
101. DALDORFF S, Mathiesen RM, Yri OE, Odegard HP, et al
     Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
     Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     November 2016
102. SUN J, Chia S
     Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.
     Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
103. LAMBERTINI M, Pinto AC, Ameye L, Jongen L, et al
     The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
     Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     October 2016
104. MOLLER H, Henson K, Luchtenborg M, Broggio J, et al
     Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England.
     Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
105. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
     Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
     Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
106. LAM SW, Frederiks CN, van der Straaten T, Honkoop AH, et al
     Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
     Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
107. OBIORAH I, Sengupta S, Fan P, Jordan VC, et al
     Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
     Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
     PubMed     Text format    
     
     
     
108. COLZANI E, Clements M, Johansson AL, Liljegren A, et al
     Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
     Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     September 2016
109. HOUVENAEGHEL G, Sabatier R, Reyal F, Classe JM, et al
     Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
     Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
110. CAMPBELL EJ, Tesson M, Doogan F, Mohammed ZM, et al
     The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
     Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
111. TONETTI DA, Chisamore MJ, Grdina W, Schurz H, et al
     Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
     Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
     PubMed     Text format    
     
     
     
112. LIM E, Palmieri C, Tilley WD
     Renewed interest in the progesterone receptor in breast cancer.
     Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
     PubMed     Text format    
     
     
     
113. PRESTON DL, Kitahara CM, Freedman DM, Sigurdson AJ, et al
     Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983-2008.
     Br J Cancer. 2016 Sep 13. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
114. BOSCO-LEVY P, Jove J, Robinson P, Moore N, et al
     Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
     Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     August 2016
115. JONASSON JG, Stefansson OA, Johannsson OT, Sigurdsson H, et al
     Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
     Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
116. DE MUNCK L, de Bock GH, Otter R, Reiding D, et al
     Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers.
     Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
117. SMITH A, Murphy L, Sharp L, O'Connor D, et al
     De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
     Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     July 2016
118. JONES ME, Schoemaker MJ, Wright L, McFadden E, et al
     Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
     Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
119. ZHU B, Mukherjee A, Machiela MJ, Song L, et al
     An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer.
     Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     June 2016
120. MILLICAN-SLATER RA, Sayers CD, Hanby AM, Hughes TA, et al
     Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
     Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
121. PERSSON M, Simonsson M, Markkula A, Rose C, et al
     Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
     Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
122. GRAM IT, Little MA, Lund E, Braaten T, et al
     The fraction of breast cancer attributable to smoking: The Norwegian women and cancer study 1991-2012.
     Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
123. SOGAARD M, Farkas DK, Ording AG, Sorensen HT, et al
     Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.
     Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     May 2016
124. DREW Y, Ledermann J, Hall G, Rea D, et al
     Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
     Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
     PubMed     Text format    
     
     
     
125. MELVIN JC, Purushotham AD, Garmo H, Pinder SE, et al
     Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
     Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
     PubMed     Text format    
     
     
     
126. WARSCHKOW R, Cerny T, Schmied BM, Guller U, et al
     A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction.
     Br J Cancer. 2016 May 17. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     
127. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
     Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
     Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     March 2016
128. BROWN JS, Kaye SB, Yap TA
     PARP inhibitors: the race is on.
     Br J Cancer. 2016;114:713-5.
     PubMed     Text format    
     
     
     
129. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
     Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
     Br J Cancer. 2016;114:777-86.
     PubMed     Text format     Abstract available
     
     
     
130. PHI XA, Saadatmand S, De Bock GH, Warner E, et al
     Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
     Br J Cancer. 2016;114:631-7.
     PubMed     Text format     Abstract available
     
     
     
131. LOUSDAL ML, Kristiansen IS, Moller B, Stovring H, et al
     Effect of organised mammography screening on stage-specific incidence in Norway: population study.
     Br J Cancer. 2016;114:590-6.
     PubMed     Text format     Abstract available
     
     
     February 2016
132. THOMSON AH, McGrane J, Mathew J, Palmer J, et al
     Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
     Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
     PubMed     Text format     Abstract available
     
     
     January 2016
133. HAMY-PETIT AS, Belin L, Bonsang-Kitzis H, Paquet C, et al
     Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
     Br J Cancer. 2016;114:44-52.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: